RGEN Repligen Corporation

35.64
+0  (1%)
Previous Close 35.35
Open 35.51
Price To book 7.09
Market Cap 1.21B
Shares 33,845,000
Volume 104,301
Short Ratio 15.43
Av. Daily Volume 221,092

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL received June 22, 2012.
RG1068
Detection of pancreatic duct abnormalities

Latest News

  1. ETFs with exposure to Repligen Corp. : April 21, 2017
  2. Repligen to Report First Quarter 2017 Financial Results
  3. Stocks Flat But Alphabet, Lockheed Martin Hit New Highs
  4. Top 3 Healthcare Penny Stocks for 2017
  5. Repligen Corp. :RGEN-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
  6. Edited Transcript of RGEN earnings conference call or presentation 22-Feb-17 1:30pm GMT
  7. Repligen beats 4Q profit forecasts
  8. Repligen Reports Fourth Quarter 2016 Financial Results, Provides Guidance for 2017
  9. Repligen Corp. breached its 50 day moving average in a Bullish Manner : RGEN-US : February 21, 2017
  10. Repligen To Report Fourth Quarter and Full Year 2016 Financial Results, Provides Financial Guidance for 2017
  11. The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen
  12. Repligen Corp. – Value Analysis (NASDAQ:RGEN) : January 3, 2017
  13. 3 Overlooked Drug Stocks to Watch Out for in 2017
  14. Repligen Corp. breached its 50 day moving average in a Bearish Manner : RGEN-US : January 2, 2017
  15. Blog Coverage Repligen Acquires Maker of Tangential Flow Filtration Cassettes
  16. Novasep Sells U.S. Subsidiary TangenX Technology Corporation, Innovator in Tangential Flow Filtration for Biopharmaceuticals